Newsroom
Our latest developments
Orca Bio’s announcements and press releases
February 16, 2023:
Orca Bio Presents Positive Data Reinforcing Clinical Profile of Orca-T and Orca-Q at 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 06, 2023:
Orca Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 12, 2022:
Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting
December 10, 2022:
Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th Annual Meeting
November 3, 2022:
Orca Bio to Present Four Abstracts at the 64th American Society of Hematology Annual Meeting, Including Updated Relapse-Free Survival Data with Orca-T and the First Clinical Data for Orca-Q
September 8, 2022:
Orca Bio Expands Manufacturing Capabilities to Develop and Commercialize its Precision Cell Therapies
August 2, 2022:
Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.
May 12, 2022:
Orca Bio to Present New Clinical Data on Orca-T at the European Hematology Association 2022 Congress
April 25, 2022:
Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings
January 06, 2022:
Orca Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 11, 2021:
Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting
November 4, 2021:
Orca Bio to Present New Clinical Data on Orca-T at the 63rd American Society of Hematology Annual Meeting
February 11, 2021:
Orca Bio Announces Updated Orca-T Clinical Data Presented at the 2021 TCT Meetings of ASTCT and CIBMTR
January 6, 2021:
Orca Bio to Present at the 39th Annual J.P Morgan Healthcare Conference
First Clinical Data From Ongoing Orca-T Trial Shows Significantly Improved 12-Month GRFS in Blood Cancer Patients Receiving an HSCT
November 4, 2020:
Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd ASH Annual Meeting
October 14, 2020:
Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T
September 2, 2020:
Orca Bio and Lyell Immunopharma Announce Research Partnership
June 17, 2020:
Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy
